Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital.

Autor:	Agnihotri A; Department of Pharmacology, Amrita School of Medicine, Faridabad, IND., Ramasubbu SK; Department of Pharmacology, Andaman and Nicobar Islands Institute of Medical Sciences, Port Blair, IND., Bandyopadhyay A; Department of Pharmacology, All India Institute of Medical Sciences, Kalyani, Kalyani, IND., Bidarolli M; Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND., Nath UK; Department of Medical Oncology and Hematology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND., Das B; Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 May 17; Vol. 16 (5), pp. e60492. Date of Electronic Publication: 2024 May 17 (Print Publication: 2024).
DOI:	10.7759/cureus.60492
Abstrakt:	Introduction Cancer chemotherapy regimens include multiple classes of adjuvant drugs as supportive therapy. Because of the concurrent intake of other drugs (like antiemetics, antidepressants, analgesics, and antimicrobials), there is a heightened risk for possible QT interval prolongation. There is a dearth of evidence in the literature regarding the usage of QT-prolonging anticancer drugs and associated risk factors that have the propensity to prolong QT interval. The purpose was to explore the extent of the use of QT-interval-prolonging drugs and potential QT-prolonging drug-drug interactions (QT-DDIs) in cancer patients attending OPD in a tertiary-care hospital. Methods This was a hospital-based, cross-sectional, observational study. Risk stratification of QT-prolonging drugs for torsades de pointes (TdP) was done by the Arizona Center for Education and Research on Therapeutics (AzCERT)/CredibleMeds-lists, and potential QT-DDIs were determined with four online DDI-checker-software. Results In 1331 cancer patients, the overall prevalence of potential QT-prolonging drug utilization was 97.3%. Ondansetron, pantoprazole, domperidone, and olanzapine were the most frequent QT-prolonging drugs in cancer patients. The top six antineoplastics with potential QT-prolonging and torsadogenic actions were capecitabine, oxaliplatin, imatinib, bortezomib, 5-fluorouracil, and bendamustine. Evidence-based pragmatic QTc interval prolongation risk assessment tools are imperative for cancer patients. Conclusion This study revealed a high prevalence of QT-prolonging drugs and QT-DDIs among cancer patients who are treated with anticancer and non-anticancer drugs. As a result, it's critical to take precautions, stay vigilant, and avoid QT-prolonging in clinical situations. Evidence-based pragmatic QTc interval prolongation risk assessment tools are needed for cancer patients. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Agnihotri et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu